Skip to content

MDMA research published in 2015

Page 3 of 3: studies 41 to 43 of 43, newest first. Back to the MDMA overview

Studies

Making a medicine out of MDMA.

The British Journal of Psychiatry 2015 Ben Sessa, David Nutt 36 citations

From its first use 3,4,-methylenedioxymethamphetamine (MDMA) has been recognised as a drug with therapeutic potential. Research on its clinical utility stopped when it entered the recreational drug scene but has slowly resurrected in the past decade. Currently there is enough evidence for MDMA to be removed from its Schedule 1 status of 'no medical use' and moved into Schedule 2 (alongside...

The variability of ecstasy tablets composition in Brazil.

Journal of Forensic Sciences 2015 Loraine R Togni, Rafael Lanaro, Rodrigo R Resende et al. 54 citations

The content of ecstasy tablets has been changing over the years, and nowadays 3,4-methylenedioxymethamphetamine (MDMA) is not always present in the tablets. The aim of this study was to investigate the chemical composition in the seized tablets labeled as ecstasy. We analyzed samples from 150 different seizures made by Sao Paulo's State Police by gas chromatography-mass spectrometry. MDMA was...

DOI: 10.1111/1556-4029.12584 (opens in new tab) Full text (opens in new tab) MDMA Chemical profiling Designer drugs Forensic science +4

Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions

BioMed Research International 2015 Débora González, Marta Torrens, Magı́ Farré 44 citations

Background . 2C-B (Nexus) is one of the most widespread novel psychoactive substances. There is limited information about its pharmacological properties, and few studies in humans concern its acute and chronic effects. 2C-B has been classified as a stimulant, hallucinogen, entactogen, and/or empathogen. Objectives . To evaluate the emotional, subjective, and cardiovascular effects of 2C-B....